EN DE
Watch HLS Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HLS Therapeutics Inc (HLS) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of HLS Therapeutics Inc stock C$8.55, price C$3.70, upside +131.1%, quality 60 out of 100. Rating: strongly undervalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA40390B1094

HT HLS Therapeutics Inc logo Some data Nov 8, 2026

HLS Therapeutics Inc

HLS · TO

Cheap (57% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value C$8.55 · Strongly undervalued 
Quality 60/100 
Generates free cash flow 
Even on cautious assumptions the value is 77% above the price (C$6.56). 
Moderate debt 
Mixed vs. peers (5/11) 
Some data 
Falling price (downtrend) 
Weak Growth (revenue 5y +0.1 %/yr in USD) 
Loss-making · -15.2% net margin (TTM) 
Narrow moat 12/100
Watch HLS Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$19.62 C$3.01 Fair Value C$8.55 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range C$3.01 – C$19.62 · fair‑value band C$6.56 – C$11.45 · the C$3.70 price screens below the C$8.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow HLS Therapeutics in your weekly email

Every Wednesday you see whether HLS Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally.

Show moreShow less

The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease.

It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels.

In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Stock analysis

HLS Therapeutics Inc (HLS) currently trades at C$3.70, while our model-based Fair Value estimate is C$8.55, implying the stock looks roughly 57% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of C$8.22 per share, and 10 of the 10 models we run sit above the C$3.70 price.

Bear case: the Growth DCF group reads lowest at C$7.96, and 0 of the 10 models stay below the price. Data coverage for this calculation is medium.

Scenario range: C$6.56 (bear) to C$11.45 (bull), the price of C$3.70 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

HLS Therapeutics Inc reported revenue of $56.5M in FY2025 versus $60.0M in FY2021, a compound −1.5%/yr. Reported net income was −$12.6M in FY2025.

Key figures

Market cap C$115M (≈ $80.5M) Micro · P/S ratio 2.51 · EPS (TTM) C$−0.3700 · Net margin −22.4% · Return on equity −14.1% · Return on assets (EBIT) −4.1% (5-year average) · Operating margin −7.9% · Revenue (TTM) $56.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 131%, HLS screens cheaper than that median.

Fair Value models

Bear C$6.56 Fair Value C$8.55 Bull C$11.45
Price C$3.70 · Upside +131.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF C$6.46 C$8.62 C$11.65 81
Growth DCF C$6.62 C$8.63 C$11.30 80
Owner Earnings C$5.83 C$7.82 C$10.62 77
All 10 models by family
DCF Models
FCF DCF C$6.46 C$8.62 C$11.65 81
Owner Earnings C$5.83 C$7.82 C$10.62 77
5Y Revenue Exit C$4.85 C$7.12 C$10.10 73
5Y EBITDA Exit C$6.23 C$9.50 C$13.42 75
10Y Revenue Exit C$5.39 C$7.34 C$9.55 68
10Y EBITDA Exit C$6.26 C$8.74 C$11.56 69
Multiples
EV/EBITDA C$6.97 C$9.88 C$12.78 67
EV/Revenue C$3.71 C$6.06 C$8.40 52
Growth DCF
Growth DCF C$6.62 C$8.63 C$11.30 80
Rev-Margin DCF C$4.85 C$7.29 C$10.13 73

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 48
Are margins and returns getting better?
Cashflow 98
Do the profits arrive as real cash?
Financial strength 38
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 71
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 91
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 20/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−0.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
Start year 2020 (pandemic)
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−20.1% (2020) → −7.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −6.6% a year for the price and +5.9% for the forecasts.
Forecast 2026 (sales)+3.3%
Forecast 2027 (sales)+11.5%
Projected 2028 (sales)+10.3%
Projected 2029 (sales)+9.1%
Projected 2030 (sales)+8.0%

Watch HLS, get fair value alerts →

Compare HLS Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 60 · Above median
Fair Value upside +131.1% · Top 25%
Profitability
Return on assets −9.2% · Bottom 25%
Net margin (12 months) −15.2% · Bottom 25%
Operating margin (12 months) −7.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 3.5% · Below median
Balance sheet
Debt / equity 0.72× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.31× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.43× · Cheaper than median
Price / free cash flow (fiscal year) 5.1× · Cheapest 25%
EV/EBITDA 6.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 18
FUTURE (revenue growth)18 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)64 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.96 $113.53 +37% vs HLS
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.93 ¥53.04 +11% vs HLS
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,885 ₹1,983 +5% vs HLS
Haleon plc HLN $9.09 $8.62 −5% vs HLS
Merck KGaA MRK €148.15 €108.83 −27% vs HLS
Galderma Group GALD CHF 194.40 CHF 111.92 −42% vs HLS
Takeda Pharmaceutical Company TAK $21.12 $11.34 −46% vs HLS
Teva Pharmaceutical Industries Limited TEVA $43.65 $20.74 −52% vs HLS
Sandoz Group SDZ CHF 86.90 CHF 40.54 −53% vs HLS
Divi's Laboratories Limited DIVISLAB ₹11,485 ₹1,567 −86% vs HLS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HLS Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HLS Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/HLS

Frequently asked questions

Is HLS Therapeutics Inc (HLS) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of C$8.55 versus a price of C$3.70, about +131% upside (undervalued).
What is the fair value of HLS?
Our model-based fair value for HLS Therapeutics Inc is C$8.55 (as of Nov 8, 2026), built from audited fundamentals. The current price: C$3.70.
What is the quality score of HLS?
HLS Therapeutics Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HLS Therapeutics Inc (HLS)?
Our model-based price target is the fair value of C$8.55 (as of Nov 8, 2026) from 10 valuation models. Cautious scenario C$6.56, optimistic scenario C$11.45. It is a calculation from audited fundamentals, not an analyst target.
What is the HLS Therapeutics Inc stock forecast for 2026?
Our models put fair value at C$8.55, about +131% upside versus a price of C$3.70 (undervalued). Cautious scenario C$6.56, optimistic scenario C$11.45. The calculation is refreshed regularly with new filings.
What is the revenue of HLS Therapeutics Inc (HLS)?
HLS Therapeutics Inc reported trailing-twelve-month revenue of about $56.2M (latest available figure, as of Nov 8, 2026).
What growth is priced into HLS Therapeutics Inc (HLS)?
For today's price to be fair in a discounted-cash-flow model, HLS Therapeutics Inc would have to grow free cash flow by -4.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.1 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of HLS use?
Our models discount HLS Therapeutics Inc at 11.8 %: a base by market capitalisation (micro), damped by beta 0.76, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HLS Therapeutics Inc that is -4.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has HLS Therapeutics Inc (HLS) delivered so far?
Over the past 5 years revenue at HLS Therapeutics Inc grew +0.1 % a year. The price currently implies free-cash-flow growth of -4.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HLS Therapeutics Inc (HLS) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into HLS Therapeutics Inc (-4.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HLS Therapeutics Inc (HLS)?
The free-cash-flow yield on the price is 19.48 %: that much free cash flow HLS Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HLS Therapeutics Inc (HLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HLS Therapeutics Inc it is C$8.55 per share (as of Nov 8, 2026), against a price of C$3.70. It is the blended result of 10 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is HLS Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, HLS trades below its calculated fair value: price C$3.70, fair value C$8.55, a gap of about +131% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HLS?
No. The price is what the market pays today (C$3.70); the fair value is what the company's own numbers justify (C$8.55). For HLS Therapeutics Inc the two are C$4.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is HLS Therapeutics Inc worth?
The market values HLS Therapeutics Inc at about C$115M (market capitalisation, as of Nov 8, 2026). Per share that is C$3.70; our models calculate a fair value of C$8.55 per share.
What do the bullish and bearish scenarios say about HLS?
Our models span a range for HLS Therapeutics Inc: cautious scenario C$6.56, base C$8.55, optimistic C$11.45 per share (as of Nov 8, 2026, price C$3.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HLS Therapeutics Inc (HLS)?
Balance-sheet figures for HLS Therapeutics Inc (as of Nov 8, 2026): return on equity −14.1%, debt of 0.72 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is HLS from its 52-week high?
HLS Therapeutics Inc trades at C$3.70, about 28% below its 52-week high of C$5.14 and 3% above the low of C$3.60 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of C$8.55 is for.
Which stocks are comparable to HLS Therapeutics Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HLS Therapeutics Inc stock attractive at the current price?
The data as of Nov 8, 2026: price C$3.70, calculated fair value C$8.55 (+131%), Quality Score 60/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HLS calculated?
We run HLS Therapeutics Inc through 10 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of C$8.55 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. HLS Therapeutics Inc currently trades 57% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HLS Therapeutics Inc (HLS)?
The closing price on Nov 12, 2026 was C$3.70. Our model-based fair value is C$8.55, about +131% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HLS Therapeutics Inc right now?
The price is below even our cautious bear case (C$6.56). The market is more pessimistic than our downside scenario. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of HLS Therapeutics Inc

How large is the market capitalisation of HLS Therapeutics Inc (HLS)?
The market capitalisation of HLS Therapeutics Inc is C$115M (≈ $80.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HLS Therapeutics Inc (HLS)?
The price-to-sales ratio of HLS Therapeutics Inc is 2.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HLS Therapeutics Inc (HLS)?
Earnings per share at HLS Therapeutics Inc are C$−0.3700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of HLS Therapeutics Inc (HLS)?
The net margin of HLS Therapeutics Inc is −22.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HLS Therapeutics Inc (HLS)?
The return on equity (ROE) of HLS Therapeutics Inc is −14.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HLS Therapeutics Inc (HLS)?
On an EBIT basis the return on assets of HLS Therapeutics Inc is −4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HLS Therapeutics Inc (HLS)?
The operating margin of HLS Therapeutics Inc is −7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HLS Therapeutics Inc (HLS)?
Revenue at HLS Therapeutics Inc is growing +3.5% versus a year earlier (3y avg −2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does HLS Therapeutics Inc (HLS) carry?
The net debt of HLS Therapeutics Inc is $38.0M (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch HLS Therapeutics Inc in the live analysis

One click puts HLS Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.